By Nick Paul Taylor The Fenwick & West analysis of life science venture capital investment in 2012 is a downbeat read. Equity investments dropped 19% and the number of first round financings fell...
A new genomics upstart has taken flight to create a new way of mobilizing personal DNA data. Miinome aims to offer a unique personal genetic marketplace, serving as a broker between peoples' genetic info and buyers of the data.
In a move to expand, personal genomics company 23andMe has rallied investors for a $50 million Series D round of financing. The fourth-round financing came with news that the company, which had offered its personal genetic test for about $300, is cutting the price to $99.
Anne Wojcicki co-founded 23andMe in 2006 with the big idea that informing patients about their genetics would empower them to take control of their health destinies rather than becoming slaves to the healthcare system. With more than 180,000 people who have had 23andMe analyze their genes, Wojcicki has turned the big idea into reality for many of those who have used its personal genomics service. Read the feature >>
Each of these women has been inspired and advised by others before them, and several cited the ability and willingness to surround themselves with strong mentors and to pass on their knowledge to others. Paula Brown Stafford, president of clinical development at Quintiles, spends much of her time serving as an adviser to others. And as Andrea Pfeifer of AC Immune (a 2012 Fierce 15 company ) put it, as a woman in a position of power in this industry, "you become a little bit of a model for young people." Read the full report >>
23andMe says it has begun filing documents to seek a formal 510(k) clearance for 7 of its genetic tests. About 100 more will be submitted for clearance in separate installments by the end of the year.
Personal genomics outfit 23andMe has expanded its presence in patient-driven research, gaining new tools and expertise in online collection of patients' disease information with its purchase of CureTogether.
The Mountain View, CA-based company has begun to build a portfolio of intellectual property based on the firm's research, expecting its first patent to be issued today to cover the firm's discovery of an SGK1 gene variant.
Brin has put some serious dollars behind the R&D efforts, spending $132 million so far to fund programs through the Michael J. Fox Foundation and discovery work at pharma giants Pfizer and GlaxoSmithKline, Bloomberg reports.
Even with a one-cent price tag, a single sequenced genome doesn't provide much value to those in pursuit of personalized treatments. Yet when thousands of genomes are sequenced, there's a...